NASDAQ:GEHC • US36266G1076
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GE HEALTHCARE TECHNOLOGY (GEHC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-21 | BTIG | Reiterate | Buy -> Buy |
| 2026-04-17 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-04-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-04-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-04-06 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-03-19 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-09 | BTIG | Reiterate | Buy -> Buy |
| 2026-02-06 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-05 | Stifel | Maintains | Buy -> Buy |
| 2026-02-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-05 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-04 | BTIG | Maintains | Buy -> Buy |
| 2026-01-30 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-15 | UBS | Downgrade | Neutral -> Sell |
| 2026-01-07 | Stifel | Maintains | Buy -> Buy |
| 2026-01-05 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-12-11 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-12-11 | Jefferies | Maintains | Buy -> Buy |
| 2025-11-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 19.552B 6.60% | 19.672B 0.61% | 20.625B 4.84% | 22.093B 7.12% | 23.076B 4.45% | 24.148B 4.65% | 24.522B 1.55% | 25.526B 4.09% | |
| EBITDA YoY % growth | 3.045B -3.49% | 3.205B 5.25% | 3.341B 4.24% | 4.057B 21.43% | 4.353B 7.30% | 4.686B 7.65% | 5.141B 9.71% | 5.479B 6.57% | |
| EBIT YoY % growth | 2.435B -3.45% | 2.625B 7.80% | 2.763B 5.26% | 3.437B 24.39% | 3.717B 8.15% | 4.041B 8.72% | N/A | N/A | |
| Operating Margin | 12.45% | 13.34% | 13.40% | 15.56% | 16.11% | 16.73% | N/A | N/A | |
| EPS YoY % growth | 3.94 10.02% | 4.49 13.96% | 4.58 2.00% | 5.17 12.83% | 5.68 9.95% | 6.28 10.48% | 6.23 -0.72% | 6.79 9.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.07 5.68% | 1.19 12.60% | 1.28 19.95% | 1.62 12.46% | 1.20 12.00% | 1.35 12.98% | 1.42 10.95% | 1.73 6.69% | 1.34 11.77% | 1.45 7.41% | 1.52 6.73% | 1.93 11.57% |
| Revenue Q2Q % growth | 5.137B 7.54% | 5.369B 7.23% | 5.505B 7.04% | 6.089B 6.86% | 5.329B 3.74% | 5.559B 3.54% | 5.691B 3.38% | 6.395B 5.03% | 5.729B 7.51% | 5.857B 5.36% | 5.988B 5.22% | 6.699B 4.75% |
| EBITDA Q2Q % growth | 887.55M 16.02% | 939.71M 0.18% | 1.005B -7.37% | 1.204B -14.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 732.65M 16.48% | 803.02M 22.79% | 869.01M 33.08% | 1.061B 28.30% | 765.71M 4.51% | 849.25M 5.76% | 913.51M 5.12% | 1.12B 5.56% | N/A | N/A | N/A | N/A |
All data in USD
28 analysts have analysed GEHC and the average price target is 93.97 USD. This implies a price increase of 36.52% is expected in the next year compared to the current price of 68.83.
GE HEALTHCARE TECHNOLOGY (GEHC) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of GE HEALTHCARE TECHNOLOGY (GEHC) is 1.07 USD and the consensus revenue estimate is 5.14B USD.
The number of analysts covering GE HEALTHCARE TECHNOLOGY (GEHC) is 28.